The Lumella test, the new point-of-care blood test helps in early detection of Preeclampsia
The Lumella test estimates the concentration of Glycosylated Fibronectin, a new pregnancy specific biomarker to accurately assess the risk of preeclampsia.
The Lumella test requires a simple finger stick and can be performed in physician’s office/clinic in the first, second, or third trimesters, between 13 to 37 weeks of gestation.